Denise Kelly
Investment advisor Seventure Partners
Seminars
To drive microbiome-based therapeutics forward, we must address the critical gaps in data collection, statistical analysis, and validation. This workshop brings together key experts to discuss:
- Standardizing Sample Collection & Processing: Learn how improved chemistry and sequencing methods can enhance reproducibility, with insights from NIST and industry leaders
- The Impact of Biostatistics on Decision-Making: Understand how inadequate statistical analysis can mislead research and drug development, and explore biostatistical solutions tailored for microbiome studies
- Resolving Discrepancies in Bioinformatics Analyses: Examine case studies demonstrating how different computational methods yield varying conclusions from the same microbiome dataset
- Validating Microbiome-Based Biomarkers: Explore successful case studies where microbiome sequencing has been validated for diagnostic and therapeutic applications
- Engage in interactive discussions and gain practical strategies for improving microbiome data reliability, ensuring stronger translational success for therapeutics
Start-Up Showcase Immerse yourself in a showcase of cutting-edge research and technologies as short-listed microbiome start-ups unveil their unique approaches to drug development.
You, and a judging panel of experts, will meet the brilliant minds behind microbiome start-ups, understanding their expertise, commercial strategies for success and passion that drives their mission to revolutionize today’s drug development landscape.
With prizes at stake, join us for a dynamic session where microbiome start-ups take center stage and a panel of VC’s and investors decide who to award as the winner of the Microbiome Movement Start-Up Showcase 2025!
Start-up Showcase Finalists Announced!
- Kevin Horgan, Head of Research & Development, Melius MicroBiomics
- Zoe Watson, Co-Founder & Chief Executive Officer, Microvitality
The 2025 Winner Receives A Free Pass to Attend Next Years’ Summit & a Speaking Position!
- Understanding the cautious approach of large pharma towards microbiome investments and the factors shaping their decisions
- Analyzing recent strategic partnerships and investment trends to uncover what drives value in microbiome-based innovations
- Discussing key considerations for forging successful partnerships with big pharma and aligning biotech strategies with industry needs to drive mutual growth
